ES2976169T3 - Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante - Google Patents
Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante Download PDFInfo
- Publication number
- ES2976169T3 ES2976169T3 ES20216368T ES20216368T ES2976169T3 ES 2976169 T3 ES2976169 T3 ES 2976169T3 ES 20216368 T ES20216368 T ES 20216368T ES 20216368 T ES20216368 T ES 20216368T ES 2976169 T3 ES2976169 T3 ES 2976169T3
- Authority
- ES
- Spain
- Prior art keywords
- rvwf
- fviii
- composition
- administered
- rfviii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495884P | 2011-06-10 | 2011-06-10 | |
| US201161511901P | 2011-07-26 | 2011-07-26 | |
| US201161523790P | 2011-08-15 | 2011-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2976169T3 true ES2976169T3 (es) | 2024-07-24 |
Family
ID=46321496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20216368T Active ES2976169T3 (es) | 2011-06-10 | 2012-06-11 | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante |
| ES18173179T Active ES2860450T3 (es) | 2011-06-10 | 2012-06-11 | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante |
| ES12728919.7T Active ES2682249T3 (es) | 2011-06-10 | 2012-06-11 | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18173179T Active ES2860450T3 (es) | 2011-06-10 | 2012-06-11 | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante |
| ES12728919.7T Active ES2682249T3 (es) | 2011-06-10 | 2012-06-11 | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9272021B2 (enExample) |
| EP (3) | EP3412305B1 (enExample) |
| JP (3) | JP6347468B2 (enExample) |
| KR (3) | KR102319868B1 (enExample) |
| CN (3) | CN103732244A (enExample) |
| AR (1) | AR086904A1 (enExample) |
| AU (5) | AU2012267458A1 (enExample) |
| CA (1) | CA2838845C (enExample) |
| DK (3) | DK3858375T3 (enExample) |
| ES (3) | ES2976169T3 (enExample) |
| FI (1) | FI3858375T3 (enExample) |
| HK (1) | HK1257436A1 (enExample) |
| HR (1) | HRP20180962T1 (enExample) |
| HU (1) | HUE039317T2 (enExample) |
| LT (1) | LT2717905T (enExample) |
| MX (2) | MX350582B (enExample) |
| PL (3) | PL3858375T3 (enExample) |
| PT (3) | PT2717905T (enExample) |
| RU (2) | RU2628537C2 (enExample) |
| SG (2) | SG10201604684WA (enExample) |
| SI (1) | SI2717905T1 (enExample) |
| TR (1) | TR201808823T4 (enExample) |
| WO (1) | WO2012171031A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103732244A (zh) * | 2011-06-10 | 2014-04-16 | 巴克斯特国际公司 | 通过施用重组vwf治疗凝血疾病 |
| CN102776260B (zh) * | 2012-07-26 | 2015-04-29 | 上海泰龙生物医药科技有限公司 | 一种高效表达重组人凝血八因子的方法 |
| EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| FR3034669B1 (fr) | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| CN109804432B (zh) | 2016-04-15 | 2023-07-14 | 武田药品工业株式会社 | 提供药代动力学药物给药方案的方法和设备 |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| FI3648788T5 (fi) | 2017-07-07 | 2024-09-09 | Takeda Pharmaceuticals Co | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää |
| JP7326246B2 (ja) | 2017-07-07 | 2023-08-15 | 武田薬品工業株式会社 | 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法 |
| MX2020008294A (es) | 2018-02-06 | 2020-11-18 | Ablynx Nv | Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina. |
| CA3094644A1 (en) * | 2018-03-21 | 2019-09-26 | Baxalta Incorporated | Separation of vwf and vwf propeptide by chromatographic methods |
| EA202192140A1 (ru) * | 2019-02-01 | 2021-12-15 | Такеда Фармасьютикал Компани Лимитед | СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ) |
| JP2022547556A (ja) * | 2019-09-11 | 2022-11-14 | 武田薬品工業株式会社 | フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法 |
| CA3169996A1 (en) | 2020-02-04 | 2021-08-12 | Takeda Pharmaceutical Company Limited | Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf |
| EP4251272A4 (en) * | 2020-11-24 | 2024-10-09 | Band Therapeutics, LLC | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEEDING DISORDERS |
| WO2024124136A1 (en) * | 2022-12-09 | 2024-06-13 | Vega Therapeutics, Inc. | Von willebrand disease animal models |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4638028A (en) | 1985-04-08 | 1987-01-20 | Goodyear Tire & Rubber Company | Rubber polymerases and methods for their production and use |
| WO1986006096A1 (en) | 1985-04-11 | 1986-10-23 | The Children's Medical Center Corporation | Von willebrand factor |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| DE4435485C1 (de) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT406373B (de) * | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| AT405403B (de) * | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| US6864403B1 (en) | 1998-10-15 | 2005-03-08 | E. I. Du Pont De Nemours And Company | Plant protein disulfide isomerases |
| US20040014657A1 (en) * | 2001-11-05 | 2004-01-22 | Jan Ohrstrom | Use of blood coagulation factor XIII for treating haemophilia A |
| WO2005012354A1 (en) * | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| EP1593388A1 (en) * | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| AU2005322067B8 (en) * | 2004-12-27 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Polymer-von Willebrand factor-conjugates |
| ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| PL2167117T3 (pl) * | 2007-06-13 | 2013-01-31 | Csl Behring Gmbh | Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi |
| AU2008323768A1 (en) | 2007-11-09 | 2009-05-14 | Baxter Healthcare S.A. | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
| JP2009127455A (ja) | 2007-11-20 | 2009-06-11 | Bando Kiko Co Ltd | 往復動エンジン |
| EP2244814B1 (en) * | 2007-12-28 | 2021-06-02 | Takeda Pharmaceutical Company Limited | Recombinant vwf formulations |
| ES2298096B1 (es) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| EP2349314B1 (en) * | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| US20110072524A1 (en) * | 2009-08-04 | 2011-03-24 | Baxter International Inc. | Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A |
| EA202090067A3 (ru) | 2010-07-08 | 2020-07-31 | Баксалта Инкорпорейтид | Способ получения рекомбинантного adamts13 в культуре клеток |
| US20120006800A1 (en) | 2010-07-09 | 2012-01-12 | Illinois Tool Works Inc. | Weld bead feature communication systems and devices |
| CN103732244A (zh) * | 2011-06-10 | 2014-04-16 | 巴克斯特国际公司 | 通过施用重组vwf治疗凝血疾病 |
-
2012
- 2012-06-11 CN CN201280038870.7A patent/CN103732244A/zh active Pending
- 2012-06-11 JP JP2014514934A patent/JP6347468B2/ja active Active
- 2012-06-11 HR HRP20180962TT patent/HRP20180962T1/hr unknown
- 2012-06-11 PL PL20216368.9T patent/PL3858375T3/pl unknown
- 2012-06-11 TR TR2018/08823T patent/TR201808823T4/tr unknown
- 2012-06-11 ES ES20216368T patent/ES2976169T3/es active Active
- 2012-06-11 DK DK20216368.9T patent/DK3858375T3/da active
- 2012-06-11 PL PL12728919T patent/PL2717905T3/pl unknown
- 2012-06-11 FI FIEP20216368.9T patent/FI3858375T3/fi active
- 2012-06-11 US US13/493,926 patent/US9272021B2/en active Active
- 2012-06-11 EP EP18173179.5A patent/EP3412305B1/en active Active
- 2012-06-11 DK DK18173179.5T patent/DK3412305T3/da active
- 2012-06-11 PT PT127289197T patent/PT2717905T/pt unknown
- 2012-06-11 KR KR1020207020667A patent/KR102319868B1/ko active Active
- 2012-06-11 KR KR1020197010327A patent/KR20190041032A/ko not_active Ceased
- 2012-06-11 SI SI201231321T patent/SI2717905T1/sl unknown
- 2012-06-11 HU HUE12728919A patent/HUE039317T2/hu unknown
- 2012-06-11 ES ES18173179T patent/ES2860450T3/es active Active
- 2012-06-11 KR KR1020147000709A patent/KR101969515B1/ko active Active
- 2012-06-11 SG SG10201604684WA patent/SG10201604684WA/en unknown
- 2012-06-11 MX MX2013014543A patent/MX350582B/es active IP Right Grant
- 2012-06-11 AR ARP120102073A patent/AR086904A1/es not_active Application Discontinuation
- 2012-06-11 PT PT181731795T patent/PT3412305T/pt unknown
- 2012-06-11 EP EP12728919.7A patent/EP2717905B1/en active Active
- 2012-06-11 EP EP20216368.9A patent/EP3858375B1/en active Active
- 2012-06-11 WO PCT/US2012/041957 patent/WO2012171031A1/en not_active Ceased
- 2012-06-11 SG SG10202002591QA patent/SG10202002591QA/en unknown
- 2012-06-11 DK DK12728919.7T patent/DK2717905T3/en active
- 2012-06-11 RU RU2014100107A patent/RU2628537C2/ru active
- 2012-06-11 ES ES12728919.7T patent/ES2682249T3/es active Active
- 2012-06-11 PL PL18173179T patent/PL3412305T3/pl unknown
- 2012-06-11 LT LTEP12728919.7T patent/LT2717905T/lt unknown
- 2012-06-11 CN CN201810079423.5A patent/CN108210889A/zh active Pending
- 2012-06-11 CN CN201611071108.5A patent/CN107412743B/zh active Active
- 2012-06-11 CA CA2838845A patent/CA2838845C/en active Active
- 2012-06-11 AU AU2012267458A patent/AU2012267458A1/en not_active Abandoned
- 2012-06-11 RU RU2017102679A patent/RU2680402C2/ru active
- 2012-06-11 PT PT202163689T patent/PT3858375T/pt unknown
-
2013
- 2013-12-10 MX MX2020000083A patent/MX2020000083A/es unknown
-
2015
- 2015-12-30 US US14/985,212 patent/US20160184403A1/en not_active Abandoned
-
2016
- 2016-04-13 AU AU2016202299A patent/AU2016202299B2/en active Active
- 2016-07-12 JP JP2016137381A patent/JP6527114B2/ja active Active
-
2017
- 2017-07-20 AU AU2017206235A patent/AU2017206235B2/en active Active
-
2018
- 2018-12-27 HK HK18116648.2A patent/HK1257436A1/zh unknown
- 2018-12-28 JP JP2018246475A patent/JP2019048892A/ja active Pending
-
2020
- 2020-01-02 AU AU2020200026A patent/AU2020200026A1/en not_active Abandoned
-
2022
- 2022-03-04 AU AU2022201518A patent/AU2022201518B2/en active Active
-
2025
- 2025-02-28 US US19/067,628 patent/US20250387455A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2860450T3 (es) | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante | |
| JP7641327B2 (ja) | 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 | |
| ES2788870T3 (es) | Formulación de factor VIII | |
| ES3004108T3 (en) | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf | |
| BR112013031795B1 (pt) | Uso de fator de von willebrand recombinante (rvwf) | |
| RU2787855C2 (ru) | Лечение нарушений свертываемости крови путем введения рекомбинантного фактора виллебранда | |
| HK40056758A (en) | Treatment of coagulation disease by administration of recombinant vwf | |
| HK40056758B (en) | Treatment of coagulation disease by administration of recombinant vwf | |
| HK40001633A (en) | Treatment of coagulation disease by administration of recombinant vwf | |
| JP2023514541A (ja) | 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療 | |
| HK40001633B (en) | Treatment of coagulation disease by administration of recombinant vwf | |
| HK1196768A (en) | Treatment of coagulation disease by administration of recombinant vwf | |
| HK1196768B (en) | Treatment of coagulation disease by administration of recombinant vwf |